Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sino BiopharmaceuticalFRA:SMZ1 +3.03%87 EV-to-EBIT is 10.23 as of Aug. 22, 2026, which is 20% below its 10-year median of 12.83. GuruFocus rates FRA:SMZ1 with a GF Score™ of 87/100 and a GF Value™ of €0.53 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 373 Biotechnology companies, Sino Biopharmaceutical ranks better than 61.39% on this metric.
Sino Biopharmaceutical (FRA:SMZ1) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sino Biopharmaceutical's Enterprise Value for the quarter that ended in Dec. 2025 was €12,697 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1,099 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:SMZ1 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's EV-to-EBIT falls into.
Sino Biopharmaceutical's current Enterprise Value is €11,248 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €1,099 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (FRA:SMZ1) has a EV-to-EBIT of 10.23 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sino Biopharmaceutical and its competitors. This is 20% below median its historical median of 12.83. Over the past decade, Sino Biopharmaceutical's EV-to-EBIT has ranged from 3.28 to 28.42. According to the industry distribution chart, Sino Biopharmaceutical ranks #144 out of 373 companies in the Biotechnology industry, placing it in the top 38.6%.
Is Sino Biopharmaceutical's EV-to-EBIT too high?
Sino Biopharmaceutical's current EV-to-EBIT of 10.23 is 20% below median its 10-year median of 12.83. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 28.42. The Biotechnology industry median EV-to-EBIT is 15.29. Sino Biopharmaceutical's value of 10.23 is 33.1% below this industry median. Based on the distribution chart, Sino Biopharmaceutical ranks #144 out of 373 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sino Biopharmaceutical has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sino Biopharmaceutical ranks #144 out of 373 companies for EV-to-EBIT. This puts Sino Biopharmaceutical in the upper half of its industry. The industry median EV-to-EBIT is 15.29. Sino Biopharmaceutical's value of 10.23 is 33.1% below this benchmark. Historically, Sino Biopharmaceutical's own EV-to-EBIT has ranged from 3.28 to 28.42 over the past decade. While the company's 10-year median is 12.83 vs. the industry median of 15.29, Sino Biopharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.29, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sino Biopharmaceutical's current EV-to-EBIT of 10.23 is 33.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sino Biopharmaceutical and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sino Biopharmaceutical's current EV-to-EBIT is 10.23, which is 20% below median its own 10-year median of 12.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (FRA:SMZ1) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.53, compared to a current price of €0.60 — trading 12.8% above its estimated fair value. The current EV-to-EBIT is 10.23, which is 20% below median its 10-year median of 12.83 and 33.1% below the Biotechnology industry median of 15.29. Sino Biopharmaceutical's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sino Biopharmaceutical (FRA:SMZ1), the current EV-to-EBIT is 10.23 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (FRA:SMZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be overvalued.
The current stock price of €0.60 is trading 12.8% above its estimated GF Value™ of €0.53.
GuruFocus considers Sino Biopharmaceutical to be Modestly Overvalued.
Key valuation signals for FRA:SMZ1:
EV-to-EBIT: 10.23 (20% below median its 10-year median of 12.83)
GF Value™: €0.53 vs. price of €0.60 (12.8% above fair value)
Industry Position: 33.1% below the Biotechnology median (#144 of 373)
No single metric tells the full story. See the FRA:SMZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
87GF Score
Get the complete analysis for FRA:SMZ1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:SMZ1 has been successfully added to your 
